October 19, 2023 - Angitia Biopharmaceuticals, a global clinical-stage biotechnology company focused on the discovery and development of breakthrough therapies that address the unmet medical needs of patients with serious musculoskeletal disease, announced the closing of a US$46M Series B extension financing led by Morningside Group, and syndicated by 3H Health Investment, OrbiMed, Yonghua Capital, Legend Capital, Oriza Holdings and Elikon Venture. The Series B extension financing brings the total size of the funding round to US$170M. Proceeds from the financing will be used to accelerate the global development of Angitia’s innovative drug candidates for musculoskeletal diseases including AGA111, AGA2115 and AGA2118.

Woodland Hills, California, USA – 17 Oct 2023 Angitia Biopharmaceuticals, a global clinical-stage biotechnology company focused on the discovery and development of breakthrough therapies that address the unmet medical needs of patients with serious musculoskeletal disease, announced today that the first subject has been successfully dosed in the Phase Ⅰ clinical trial of AGA2115. The First-in-Human (FIH) trial is evaluating the safety, tolerability, pharmacokinetics, and pharmacodynamics of AGA2115, an investigational therapy for the treatment of osteogenesis imperfecta (OI).

Guangzhou, China, and Woodland Hills, California, USA –16 Oct 2023: Angitia Biopharmaceuticals, a global clinical-stage biotechnology company focused on the discovery and development of breakthrough therapies that address the unmet medical needs of patients with serious musculoskeletal disease, announced today that National Medicinal Product Administration (NMPA) has approved Angitia Biopharmaceuticals’ Investigational New Drug (IND) application of the Phase III study for AGA111. Angitia has previously announced the encouraging results from AGA111’s Phase I/II trial, which demonstrated excellent safety and preliminary efficacy in lumbar interbody fusion.